Abstract
ABSTRACTBackgroundPrescribing of cyclo‐oxygenase ‐2 inhibitors (coxibs) has had an economic impact on patients and overall healthcare costs in Thailand.AimTo analyse the pattern of coxib use and to determine the cost impact of inappropriate use.MethodA random retrospective sample was selected from two months of prescribing data. There were 519 prescriptions for coxibs and 594 prescriptions for conventional non‐steroidal anti‐inflammatory drugs (NSAIDs). Appropriate use was based on the UK National Institute for Clinical Excellence criteria.Results208 (40%) patients receiving coxibs and 113 (19%) patients receiving conventional NSAIDs were at high risk for upper gastrointestinal adverse effects. Of those receiving coxibs, 112 (22%) received coxibs alone and 159 (31%) also received gastro‐protective agents. The cost of inappropriate use of coxibs in patients at a low risk of gastrointestinal effects was 2.4 million Baht/year. The excess cost, adjusted for the most commonly prescribed conventional NSAIDs (diclofenac 25 mg, Voltaren 25 mg, and ibuprofen 400 mg), were 3.4, 1.1 and 3.2 million Baht/year, respectively.ConclusionInappropriate use of coxibs resulted in excessive expenditure and specific pharmacy intervention would be required to reduce the cost impact.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
